{
    "clinical_study": {
        "@rank": "104356", 
        "acronym": "Phase-0-MM", 
        "arm_group": [
            {
                "arm_group_label": "Melphalan", 
                "arm_group_type": "Experimental", 
                "description": "A microdose of 2 mg/m2 iv Melphalan (1% of standard dose) is given two hours prior to planned standard dose Melphalan"
            }, 
            {
                "arm_group_label": "Bortezomib", 
                "arm_group_type": "Experimental", 
                "description": "A microdose of 0.013 mg/m2 iv Bortezomib (1% of standard dose) is given two hours prior to planned standard dose Bortezomib"
            }, 
            {
                "arm_group_label": "Dexamethasone", 
                "arm_group_type": "Experimental", 
                "description": "A microdose of 0.4 mg iv Dexamethasone (1% of standard dose) is given two hours prior to planned standard dose of Dexamethasone"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to identify specific genes that are up- or downregulated in\n      multiple myeloma patients who receive a microdose of either Melphalan (Alkeran\u00ae), Bortezomib\n      (Velcade\u00ae) or Dexamethasone (Dexaven\u00ae). The study treatment constitutes 1% of the planned\n      standard myeloma treatment and will be given two hours prior to standard treatment. Blood\n      samples are taken at baseline, 15, 30, 60 and 120 minutes for microarray analysis."
        }, 
        "brief_title": "Microdose Study of Melphalan, Bortezomib and Dexamethasone", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Planned treatment for Multiple Myeloma (newly diagnosed as well as relapse and\n             refractory disease) with one of the following chemotherapy regimens: 1) Highdose\n             melphalan, 2) Bortezomib or 3) Dexamethasone\n\n          -  18 years or older.\n\n          -  Understand and have the will to sign the informed consent.\n\n        Exclusion Criteria:\n\n          -  Prior treatment with the study drug\n\n          -  Received treatment with biphosphonates in the week prior to study treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "21", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02109861", 
            "org_study_id": "KFE2011.06", 
            "secondary_id": "2011-003791-37"
        }, 
        "intervention": [
            {
                "arm_group_label": "Melphalan", 
                "description": "A microdose of 2 mg/m2 iv Melphalan (1% of standard dose) is given two hours prior to planned standard dose Melphalan", 
                "intervention_name": "Melphalan", 
                "intervention_type": "Drug", 
                "other_name": "Alkeran\u00ae"
            }, 
            {
                "arm_group_label": "Bortezomib", 
                "description": "A microdose of 0.013 mg/m2 iv Bortezomib (1% of standard dose) is given two hours prior to planned standard dose Bortezomib", 
                "intervention_name": "Bortezomib", 
                "intervention_type": "Drug", 
                "other_name": "Velcade\u00ae"
            }, 
            {
                "arm_group_label": "Dexamethasone", 
                "description": "A microdose of 0.4 mg iv Dexamethasone (1% of standard dose) is given two hours prior to planned standard dose of Dexamethasone", 
                "intervention_name": "Dexamethasone", 
                "intervention_type": "Drug", 
                "other_name": "Dexaven\u00ae)"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "Bortezomib", 
                "Melphalan", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Multiple Myeloma", 
            "Phase 0 study", 
            "Microdose study", 
            "Micro array", 
            "Gene expression profiling"
        ], 
        "lastchanged_date": "April 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Aalborg", 
                    "country": "Denmark", 
                    "zip": "9000"
                }, 
                "name": "Department of Haematology, Aalborg University Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Henrik Gregersen, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Asta Svirskaite, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase 0 Microdose Study to Evaluate the Effect of Melphalan, Bortezomib and Dexamethasone on Cellular Gene-expression in Patients With Multiple Myeloma", 
        "overall_contact": {
            "email": "henrik.gregersen@rn.dk", 
            "last_name": "Henrik Gregersen, MD, PhD", 
            "phone": "+45 99 32 63 26"
        }, 
        "overall_contact_backup": {
            "email": "assv@rn.dk", 
            "last_name": "Asta Svirskaite, MD", 
            "phone": "+45 99 32 63 59"
        }, 
        "overall_official": {
            "affiliation": "Aalborg University Hospital, Department of Haematology, 9000 Aalborg, Denmark", 
            "last_name": "Henrik Gregersen, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Denmark: Danish Dataprotection Agency", 
                "Denmark: The Regional Committee on Biomedical Research Ethics", 
                "Denmark: Danish Health and Medicines Authority"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome measure is determination of differential and significantly expressed genes across time successive samples from each individual patient. The analysis will be based on global gene expression profiling and differentially expressed genes will be identified using pairwise comparisons of samples means by two sample t-tests and corrections for multiple testing.", 
            "measure": "Change from baseline in gene expression at 15, 30, 60, 120 minutes upon microdose drug exposure.", 
            "safety_issue": "No", 
            "time_frame": "Prior to microdose and 15, 30, 60 and 120 minutes post-microdose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02109861"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Aalborg Universityhospital", 
            "investigator_full_name": "Henrik Gregersen", 
            "investigator_title": "Consultant haematologist, MD, PhD", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Aalborg Universityhospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Henrik Gregersen", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}